Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus SECOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus SECOBARBITAL SODIUM.
BUTALAN vs SECOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Secobarbital enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion influx and causing neuronal hyperpolarization, leading to CNS depression.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
Oral: 100-200 mg at bedtime for insomnia; IM: 150-200 mg as a single dose; IV: 50-250 mg as a single dose, administered slowly (not to exceed 50 mg per 15 seconds).
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is approximately 15-40 hours (mean ~30 hours) in adults. In neonates, half-life may be prolonged (up to 100 hours). Half-life increases in hepatic impairment and with advanced age.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal excretion of unchanged drug (about 25-50%) and metabolites; the remainder is eliminated via hepatic metabolism and fecal excretion. Less than 5% is excreted unchanged in feces.
Category C
Category D/X
Barbiturate
Barbiturate